Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | STS | P08842 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14849627 | 0.86 | HPGD (0.62) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL13599001 | 0.81 | HPGD (0.60) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL4512366 | 0.80 | HPGD (0.62) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL2015039 | 0.79 | HPGD (0.66) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL27530648 | 0.79 | HPGD (0.66) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL26608596 | 0.79 | HPGD (0.66) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL17109787 | 0.79 | HPGD (0.50) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL19626321 | 0.78 | HPGD (0.60) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL28195249 | 0.77 | HPGD (0.68) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL6104806 | 0.77 | HPGD (0.52) | HPGDRECQLPTPN2PTPN1PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035790-B2 | RORγ modulators | EXELIXIS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20150266856-A1 | RORGamma Modulators | EXELIXIS, INC. | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266856-A1 | RORGamma Modulators | RORB, RORA, RORC | HPGD 1227/4885RECQL 595/4885PTPN2 855/4885 |
| US-10035790-B2 | RORγ modulators | RORB, RORA, RORC | HPGD 1147/4885RECQL 665/4885PTPN2 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.